在科技巨头讲出新的叙事逻辑下，公募QDII正逐步回补美股仓位。 近期，英伟达、微软、谷歌、三星在美股密集发布对AI医疗的投资后，包括张坤等明星基金经理所管公募 QDII大举增加美股仓位，也使不少基金在近期港股调整中降低了回撤风险，借助AI医疗新叙事在近期的强 势，不少前期表现落后的QDII基金业绩加速提升。 驱动QDII基金经理在第三季度末增持美股的核心原因，是近期美股AI医疗赛道开始展现高弹性。 Wind数据显示，以近三个月的弹性收益排名计算，以美股为核心仓位的QDII基金几乎主导了业绩前五名。其 中，易方达基金旗下的易方达全球成长精选基金近三个月的收益率为39%，华夏新时代基金的同期收益率为 36%，嘉实基金旗下的嘉实全球产业基金同期收益为31%，天弘基金旗下的全球高端制造基金同期为30%，创 金合信全球医药生物基金同期收益率约28%。 根据最近一个月的收益率，几乎没有港股仓位的QDII基金，曾是业绩排名的主要受益者。建信基金旗下的建 信新兴市场混合基金近一个月收益率约为11%，在最近一个月内排名QDII第一，而创金合信全球医药生物基金 在最近一个月的收益排名第二，期间业绩回报为10%。 QDII基金强力 ...

Core Viewpoint - Public QDII funds are gradually increasing their positions in the US stock market, driven by the new narrative surrounding AI in healthcare, which has led to significant performance improvements for many funds [1][2]. Group 1: QDII Fund Positioning - Star fund managers, including Zhang Kun, have significantly increased their US stock holdings, with some funds reducing their exposure to Hong Kong stocks to mitigate risks during recent market adjustments [2][3]. - The GF Global Select Fund reported a 75% allocation to US stocks by the end of Q3, while the Hong Kong stock allocation dropped to approximately 3.72% [3]. - The E Fund Global Growth Select Fund also saw its US stock allocation rise to 52%, with only about 10% in Hong Kong stocks [3]. Group 2: Performance of QDII Funds - The core reason for the increase in US stock holdings among QDII fund managers is the high elasticity exhibited by the AI healthcare sector in the US market [5]. - QDII funds focusing on US stocks have dominated performance rankings, with the E Fund Global Growth Select Fund achieving a 39% return over the past three months [5]. - Funds with minimal exposure to Hong Kong stocks, such as the CCB New Emerging Markets Mixed Fund, reported an 11% return in the last month, ranking first among QDII funds [5]. Group 3: Investment in AI Healthcare - The recent surge in US AI healthcare investments by major companies like Nvidia, Microsoft, and Google has significantly contributed to the performance of QDII funds [6][7]. - The CCB Global Pharmaceutical Fund's manager completely liquidated its Hong Kong stock holdings, increasing its US stock allocation to 71% by the end of September [4]. - Fund managers are optimistic about the potential of AI healthcare, viewing it as a key area for growth, especially as the US leads in this sector [8][9].